An aminoquinoline antimalarial and anti-inflamatory drug.

Phase of research

Potential treatment - pre-clinical evidence

How it helps


Drug status

Used to treat other disease

Supporting references
Contradictory references
AI-suggested references
Clinical trials

General information

Amodiaquine is an aminoquinoline compound with antimalarial and anti-inflammatory activity. It might act through plasmodial heme polymerase inhibition on some Plasmodium strains resistant to chloroquine (NCIt).

Amodiaquine on DrugBank
Amodiaquine on PubChem
Amodiaquine on Wikipedia


Amodiaquine dihydrochloride


Structure image - Amodiaquine


Supporting references

Link Tested on Impact factor Notes Publication date
Human organs-on-chips as tools for repurposing approved drugs as potential influenza and COVID19 therapeutics in viral pandemics
human organ-on-a-chip Apr/14/2020
Antiviral options against SARS-CoV-2 infection
Preprint Screening
VERO E6 cell cultures

synergistic effect in combination with the virus-directed drug nelfinavir

Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro
Preprint In silico
VERO E6 cell cultures

synergistic effect in combination with nitazoxanide, arbidol or lopinavir

Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells: Nafamostat is the most potent antiviral drug candidate
Calu-3 human airway epithelial cells

higher IC50 value in Calu-3 cells than VERO E6 cells

Broad anti-coronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo
Small molecule Animal model
BALB/c mice; A549 lung adenocarcinoma cells expressing ACE2; Vero E6 cells; SARS-CoV-2 strain MA15 4.32

Inhibits the production of infectious viral particles in vitro and decreases viral gene RNA levels.

Artemisia annua L. extracts inhibit the in vitro replication of SARS-CoV-2 and two of its variants
Small molecule In vitro Mixed substance
Vero E6 cells; Calu-3 cells; SARS-CoV-2 isolates USA/WA12020, B1.1.7, and B1.351. 3.69

The compound inhibited SARS-CoV-2 (WT) in Vero E6 cells with an IC50 of 5.8 μM.


AI-suggested references

Clinical trials

ID Title Status Phase Start date Completion date
NCT04532931 COVID-19 Treatment in South Africa Completed Phase 2 Sep/03/2020 Aug/23/2021
  • Alternative id - SP-PA-COV-202
  • Interventions - Other: Standard of care (Paracetamol)|Drug: Artesunate-amodiaquine|Drug: Pyronaridine-artesunate|Drug: Favipiravir plus Nitazoxanide|Drug: Sofosbuvir/daclatasvir
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Ezintsha, Wits Reproductive Health & HIV Institute University of the Witwatersrand, Johannesburg, South Africa
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 192
  • Age - 18 Years to 65 Years   (Adult, Older Adult)
  • Outcome measures - Incidence of SARS-CoV-2 clearance|Time to clearance of nasal SARS-CoV-2|Median quantity of SARS-CoV-2|Proportion of days with fever after randomization|Proportion of days with respiratory symptoms after randomization|FLU-PRO© Plus|Serious adverse events|Adverse events resulting in treatment discontinuation|Adverse events considered related to the investigational products|LRTI|Maximum score on WHO Ordinal Scale for Clinical Improvement during study participation|Cumulative incidence of hospitalization|Days of hospitalization|Cumulative incidence of mortality